NL193216C - Diethylammonium-2-(2,6-dichlooranilino)-fenylacetaat en topicaal toepasbaar preparaat dat het bevat. - Google Patents
Diethylammonium-2-(2,6-dichlooranilino)-fenylacetaat en topicaal toepasbaar preparaat dat het bevat. Download PDFInfo
- Publication number
- NL193216C NL193216C NL8100917A NL8100917A NL193216C NL 193216 C NL193216 C NL 193216C NL 8100917 A NL8100917 A NL 8100917A NL 8100917 A NL8100917 A NL 8100917A NL 193216 C NL193216 C NL 193216C
- Authority
- NL
- Netherlands
- Prior art keywords
- active substance
- water
- dichloroanilino
- diethylammonium
- phenyl acetate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 22
- QISOABFHVQTPPA-UHFFFAOYSA-N CCNCC.CC(=O)OC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl Chemical compound CCNCC.CC(=O)OC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl QISOABFHVQTPPA-UHFFFAOYSA-N 0.000 title claims description 14
- 238000009472 formulation Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 15
- 239000003205 fragrance Substances 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940114930 potassium stearate Drugs 0.000 claims description 4
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- 239000005662 Paraffin oil Substances 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 229950004959 sorbitan oleate Drugs 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 229940049953 phenylacetate Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 229940057995 liquid paraffin Drugs 0.000 claims 1
- 239000004200 microcrystalline wax Substances 0.000 claims 1
- 235000019808 microcrystalline wax Nutrition 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 239000001589 sorbitan tristearate Substances 0.000 claims 1
- 229960004129 sorbitan tristearate Drugs 0.000 claims 1
- 235000011078 sorbitan tristearate Nutrition 0.000 claims 1
- 229940114926 stearate Drugs 0.000 claims 1
- 229940099259 vaseline Drugs 0.000 claims 1
- 239000003871 white petrolatum Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000004530 micro-emulsion Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NFEVMRNCAGDLBK-UHFFFAOYSA-N 2-anilino-2-phenylacetic acid Chemical class C=1C=CC=CC=1C(C(=O)O)NC1=CC=CC=C1 NFEVMRNCAGDLBK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JGMKRAUEFASZKH-UHFFFAOYSA-N 2-carboxyphenolate;diethylazanium Chemical compound CC[NH2+]CC.OC1=CC=CC=C1C([O-])=O JGMKRAUEFASZKH-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8105822A GB2093693B (en) | 1981-02-24 | 1981-02-24 | Pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids novel carboxylic acid salts and the production thereof |
| GB8105822 | 1981-02-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL8100917A NL8100917A (nl) | 1982-09-16 |
| NL193216B NL193216B (nl) | 1998-11-02 |
| NL193216C true NL193216C (nl) | 1999-03-03 |
Family
ID=10519933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8100917A NL193216C (nl) | 1981-02-24 | 1981-02-25 | Diethylammonium-2-(2,6-dichlooranilino)-fenylacetaat en topicaal toepasbaar preparaat dat het bevat. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US4407824A (en, 2012) |
| AT (1) | AT370721B (en, 2012) |
| CA (1) | CA1180008A (en, 2012) |
| CY (2) | CY1443A (en, 2012) |
| FR (2) | FR2500751A1 (en, 2012) |
| GB (2) | GB2093693B (en, 2012) |
| HK (1) | HK83888A (en, 2012) |
| KE (1) | KE3820A (en, 2012) |
| LU (1) | LU83945A1 (en, 2012) |
| NL (1) | NL193216C (en, 2012) |
| SE (2) | SE448088B (en, 2012) |
| SG (1) | SG33388G (en, 2012) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU83138A1 (de) * | 1981-02-16 | 1981-09-11 | T Eckert | Topische pharmazeutische praeparate,enthaltend salze von alkancarbonsaeuren sowie neue carbonsaeuresalze und verfahren zu ihrer herstellung |
| FR2526427A1 (fr) * | 1982-05-04 | 1983-11-10 | Bouchara Emile | Nouveau sel d'indometacine, son procede de preparation et les compositions pharmaceutiques en renfermant |
| US4437053A (en) * | 1982-05-10 | 1984-03-13 | Diasonics (Nmr) Inc. | Gradient power supply |
| CH655656B (en, 2012) * | 1982-10-07 | 1986-05-15 | ||
| ES8407042A1 (es) * | 1982-10-08 | 1984-09-01 | Espinos & Bofill Lab Sa | Procedimiento para la obtencion de un nuevo derivado del sulpiride. |
| JPS59137408A (ja) * | 1983-01-27 | 1984-08-07 | Taisho Pharmaceut Co Ltd | 軟膏 |
| JPS59139315A (ja) * | 1983-01-31 | 1984-08-10 | Taisho Pharmaceut Co Ltd | クリ−ム剤 |
| CH643138A5 (de) * | 1983-08-29 | 1984-05-30 | Mepha Ag | Indomethacin enthaltende, gelartige salbe. |
| DE3381733D1 (de) * | 1983-12-08 | 1990-08-16 | Toko Yakuhin Kogyo Kk | Gelpraeparate zur externen applikation. |
| US4670254A (en) * | 1983-12-09 | 1987-06-02 | Toko Yakuhin Industry Co., Ltd. | Gel preparations for topical application of diclofenac sodium |
| DE3423589A1 (de) * | 1984-06-27 | 1986-01-09 | Wella Ag, 6100 Darmstadt | Oxidationshaarfaerbemittel auf basis einer niedrigviskosen traegermasse |
| IT1178411B (it) * | 1984-09-06 | 1987-09-09 | Sigma Tau Ind Farmaceuti | Sale di d,l-lisina dell'acido 1-(4-clorobenzoil)-5-metossi-2-metil-1h-indol-3 acetico, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono |
| CA1265288A (en) * | 1984-11-22 | 1990-01-30 | E. I. Du Pont De Nemours And Company | Curable fluoroelastomer composition |
| US4980084A (en) * | 1985-09-11 | 1990-12-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Water rinsable petroleum jelly compositions |
| US4690774A (en) * | 1985-09-11 | 1987-09-01 | Chesebrough Pond's Inc. | Novel translucent water in oil emulsions |
| US4832858A (en) * | 1987-02-19 | 1989-05-23 | Chesebrough-Pond's Inc. | Water dispersible petroleum jelly compositions |
| US4960892A (en) * | 1988-06-10 | 1990-10-02 | American Home Products Corporation | Naphthalenepropionic acid derivatives as anti-inflammatory/anti-allergic agents |
| TW225536B (en, 2012) * | 1990-08-23 | 1994-06-21 | Ciba Geigy Ag | |
| US5444076A (en) * | 1990-11-26 | 1995-08-22 | Roemmers S.A.I.C.F. | Pharmaceutical preparation for topical application |
| AU2259692A (en) * | 1991-07-03 | 1993-02-11 | Sano Corporation | Composition and method for transdermal delivery of diclofenac |
| US6117907A (en) * | 1993-04-14 | 2000-09-12 | Sher; Neal A. | Topical treatment of ocular pain after corneal surgery |
| JP3526887B2 (ja) * | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
| FI100692B (fi) * | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
| ATE178884T1 (de) * | 1994-06-29 | 1999-04-15 | Novartis Erfind Verwalt Gmbh | Salze von 2-((2,6- dichlorophenyl)amin>phenylacetoxyessigsäure mit organischen basischen kationen |
| RU2128989C1 (ru) * | 1997-03-05 | 1999-04-20 | Закрытое акционерное общество "Химмедсинтез" | Композиция антимикробного, противовоспалительного и регенерационного действия |
| US20030060657A1 (en) * | 1998-04-28 | 2003-03-27 | Russinsky Limited | Process for the preparation of Aceclofenac |
| RU2177314C2 (ru) * | 2000-03-22 | 2001-12-27 | Кривошеин Юрий Семенович | Состав с антисептическими, репаративными и болеутоляющими свойствами |
| TWI290464B (en) | 2000-09-01 | 2007-12-01 | Novartis Consumer Health Sa | Treatment of burns |
| DE10114561A1 (de) * | 2001-03-24 | 2002-09-26 | Wella Ag | Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern |
| ITMI20020986A1 (it) * | 2002-05-10 | 2003-11-10 | Acraf | Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo |
| AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| ITMI20030269A1 (it) * | 2003-02-14 | 2004-08-15 | Advance Holdings Ltd | Sale di cetilpiridino di un agente antiinfiammatorio |
| FR2854802B1 (fr) * | 2003-05-12 | 2005-06-24 | Galderma Res & Dev | Procede de preparation d'une formulation contenant un principe actif microdose |
| EP2055298A1 (en) | 2007-10-30 | 2009-05-06 | Novartis AG | Topical composition |
| US11000495B2 (en) | 2014-09-10 | 2021-05-11 | GSK Consumer Healthcare S.A. | Topical diclofenac sodium compositions |
| CN116143647A (zh) * | 2023-03-03 | 2023-05-23 | 长沙晶易医药科技股份有限公司 | 双氯芬酸二乙胺的新晶型及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US514839A (en) * | 1894-02-13 | sergeant | ||
| GB971700A (en) * | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
| AT290523B (de) * | 1962-01-05 | 1971-06-11 | Merck & Co Inc | Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren |
| US3558690A (en) * | 1965-04-08 | 1971-01-26 | Gelgy Chemical Corp | Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation |
| CH470349A (de) * | 1966-10-07 | 1969-03-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen substituierten Phenylessigsäuren |
| US3896157A (en) * | 1967-01-13 | 1975-07-22 | Syntex Corp | Dihydo 2-naphthylacetic acid derivatives |
| US4048330A (en) * | 1967-01-13 | 1977-09-13 | Syntex Corporation | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia |
| CA960689A (en) * | 1967-01-13 | 1975-01-07 | Syntex Corporation | 2-naphthyl acetic acid derivatives and compositions |
| FR1546478A (fr) * | 1967-01-27 | 1968-11-22 | Rhone Poulenc Sa | Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation |
| US3592902A (en) * | 1967-04-13 | 1971-07-13 | Sumitomo Chemical Co | Injection |
| NL6817965A (en, 2012) * | 1967-12-20 | 1969-06-24 | ||
| US3641040A (en) * | 1968-03-27 | 1972-02-08 | Ciba Geigy Corp | Tertiary amino phenyl acetic acids |
| US3637767A (en) * | 1968-07-30 | 1972-01-25 | Syntex Corp | 2-(6'-methoxynaphth-2'-yl)propylene oxide and 5'-halo derivatives |
| BR6915470D0 (pt) * | 1969-03-24 | 1973-03-13 | Syntex Corp | Processo para preparar derivados de acido 2-(6'substituido 2'naftil)propionico e de seus sais |
| US3752826A (en) * | 1970-01-26 | 1973-08-14 | Mcneilab Inc | Aroyl substituted pyrroles |
| US3647858A (en) * | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US4033816A (en) | 1973-06-18 | 1977-07-05 | The Upjohn Company | Process for inhibiting platelet aggregation |
| US3936528A (en) * | 1974-02-13 | 1976-02-03 | Syntex Corporation | Analgesic formulations having enhanced therapeutic activity |
| ES423834A1 (es) * | 1974-03-02 | 1976-06-01 | Roger Lab | Procedimiento de obtencion de una nueva sal de piperacina del acido (1 - p - clorobenzoil - 2 - metil - 5 - metoxi - 3- indolil) acetico. |
| US4031243A (en) * | 1975-07-03 | 1977-06-21 | Juste, S.A. Quimico-Farmaceutica | 2-(4-Isobutyl phenyl)butyric acid, salts thereof, and pharmaceutical compositions containing the same |
| PT66660B (en) * | 1976-06-12 | 1978-11-13 | Ciba Geigy Ag | Process for the production of a derivative of phenylacetic |
| LU77316A1 (en, 2012) * | 1977-05-11 | 1979-01-19 | ||
| JPS549240A (en) * | 1977-06-23 | 1979-01-24 | Asahi Chem Ind Co Ltd | New derivative of phenylglycolic acid, its preparation and analgesic and antiinflammatory agent contining it as effective component |
| GB2023000B (en) * | 1978-06-17 | 1982-10-13 | Kowa Co | Antinflammatory analgesic gelled ointments |
| BE871335A (fr) * | 1978-10-18 | 1979-04-18 | Bago Sa Labor | Derives solubles des acides 2-anilino-aryl-carboxyliques substitues utiles par la voie buccale comme agents anti-inflammatoires. |
| LU83138A1 (de) * | 1981-02-16 | 1981-09-11 | T Eckert | Topische pharmazeutische praeparate,enthaltend salze von alkancarbonsaeuren sowie neue carbonsaeuresalze und verfahren zu ihrer herstellung |
-
1981
- 1981-02-16 AT AT0070981A patent/AT370721B/de not_active IP Right Cessation
- 1981-02-17 SE SE8101064A patent/SE448088B/sv not_active IP Right Cessation
- 1981-02-19 CA CA000371271A patent/CA1180008A/en not_active Expired
- 1981-02-20 US US06/236,097 patent/US4407824A/en not_active Expired - Lifetime
- 1981-02-24 GB GB8105822A patent/GB2093693B/en not_active Expired
- 1981-02-25 NL NL8100917A patent/NL193216C/nl not_active IP Right Cessation
- 1981-02-27 FR FR8103932A patent/FR2500751A1/fr active Granted
- 1981-10-09 FR FR8119055A patent/FR2514348A1/fr active Granted
-
1982
- 1982-02-15 LU LU83945A patent/LU83945A1/de unknown
- 1982-05-25 SE SE8203228A patent/SE8203228L/xx unknown
-
1983
- 1983-07-27 US US06/517,606 patent/US4551475A/en not_active Expired - Lifetime
-
1984
- 1984-07-16 GB GB08418021A patent/GB2143528B/en not_active Expired
-
1985
- 1985-08-14 US US06/765,416 patent/US4619926A/en not_active Expired - Lifetime
-
1988
- 1988-02-18 US US07/156,770 patent/US4784808A/en not_active Expired - Lifetime
- 1988-05-27 SG SG33388A patent/SG33388G/en unknown
- 1988-06-07 KE KE3820A patent/KE3820A/xx unknown
- 1988-10-13 HK HK838/88A patent/HK83888A/xx not_active IP Right Cessation
-
1989
- 1989-03-10 CY CY1443A patent/CY1443A/en unknown
- 1989-03-10 CY CY1444A patent/CY1444A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2143528B (en) | 1985-10-02 |
| SE8203228L (sv) | 1982-08-18 |
| GB2093693B (en) | 1985-10-02 |
| SG33388G (en) | 1988-09-30 |
| CY1444A (en) | 1989-03-10 |
| FR2500751B1 (en, 2012) | 1984-12-28 |
| ATA70981A (de) | 1982-09-15 |
| FR2514348A1 (fr) | 1983-04-15 |
| KE3820A (en) | 1988-09-09 |
| US4407824A (en) | 1983-10-04 |
| CA1180008A (en) | 1984-12-27 |
| US4619926A (en) | 1986-10-28 |
| FR2514348B1 (en, 2012) | 1984-12-14 |
| NL8100917A (nl) | 1982-09-16 |
| AT370721B (de) | 1983-04-25 |
| NL193216B (nl) | 1998-11-02 |
| HK83888A (en) | 1988-10-21 |
| FR2500751A1 (fr) | 1982-09-03 |
| US4551475A (en) | 1985-11-05 |
| GB2143528A (en) | 1985-02-13 |
| GB8418021D0 (en) | 1984-08-22 |
| LU83945A1 (de) | 1982-12-13 |
| SE8101064L (sv) | 1982-08-18 |
| CY1443A (en) | 1989-03-10 |
| GB2093693A (en) | 1982-09-08 |
| US4784808A (en) | 1988-11-15 |
| SE448088B (sv) | 1987-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL193216C (nl) | Diethylammonium-2-(2,6-dichlooranilino)-fenylacetaat en topicaal toepasbaar preparaat dat het bevat. | |
| CA1228812A (en) | Process for the manufacture of novel topically administrable pharmaceutical compositions | |
| US4661524A (en) | Topical treatment and composition | |
| US4975466A (en) | Pharmaceutical preparations for topical application and their use in the treatment of inflammatory skin diseases | |
| JPH0447649B2 (en, 2012) | ||
| JPH024335B2 (en, 2012) | ||
| US6328980B1 (en) | Emulsion composition comprising a fluorohydrocarbon compound and a method for preparing | |
| DE3205077A1 (de) | Ammoniumsalze substituierter carbonsaeuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische praeparate | |
| CA2074503C (en) | Pharmaceutical formulation containing penciclovir | |
| EP0131790A2 (de) | Etofenamat-Zubereitung | |
| DE3122791C2 (en, 2012) | ||
| EP0130516B1 (de) | Etofenamat-Zubereitung | |
| EP0548145A1 (en) | Topical treatment and composition | |
| DK161515B (da) | Analogifremgangsmaade til fremstilling af diethylammoniumsalt af o-(2,6-dichloranilino)-phenyleddikesyre | |
| GB2137091A (en) | Antimycotic Agent With a High Release of Active Compounds, in the Form of a Cream | |
| FR2736639A1 (fr) | Nouveaux composes hydrofluorocarbones a fonction thioester, procede de preparation, utilisations et compositions les comprenant | |
| KR890004345B1 (ko) | 알칸카복실산염의 제조방법 | |
| JPH0521907B2 (en, 2012) | ||
| CA2156396A1 (en) | Stable dermatologic preparation containing mycophenolic acid | |
| BE887671A (fr) | Preparations pharmaceutiques topiques contenant des sels d'acides alcane-carboxyliques ainsi que de nouveaux sels d'acides carboxyliques et leurs procedes de preparation | |
| CH651474A5 (en) | Topical pharmaceutical products containing salts of alkanecarboxylic acids | |
| IE50921B1 (en) | Pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids,novel carboxylic acid salts and the production thereof | |
| HU186382B (en) | Process for producing substituted alkane-carboxylic acides and salts and pharmaceutical compositions containing them as active agents | |
| DD156595A5 (de) | Verfahren zur herstellung von salzen von alkancarbonsaeuren und von pharmazeutischen praeparaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BT | A notification was added to the application dossier and made available to the public | ||
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| CNR | Transfer of rights (patent application after its laying open for public inspection) |
Free format text: NOVARTIS AG |
|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Free format text: 20010225 |